Wall Street analysts forecast that Zafgen Inc (NASDAQ:ZFGN) will announce ($0.43) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Zafgen’s earnings, with estimates ranging from ($0.45) to ($0.39). Zafgen reported earnings per share of ($0.48) during the same quarter last year, which indicates a positive year-over-year growth rate of 10.4%. The business is scheduled to issue its next earnings report on Tuesday, March 5th.
According to Zacks, analysts expect that Zafgen will report full year earnings of ($1.96) per share for the current financial year, with EPS estimates ranging from ($2.01) to ($1.91). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.76) per share, with EPS estimates ranging from ($2.23) to ($1.28). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Zafgen.
Zafgen (NASDAQ:ZFGN) last issued its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.04.
ZFGN traded up $0.04 during trading on Monday, hitting $5.12. The company’s stock had a trading volume of 163,960 shares, compared to its average volume of 503,863. The company has a current ratio of 11.78, a quick ratio of 11.78 and a debt-to-equity ratio of 0.16. Zafgen has a twelve month low of $3.57 and a twelve month high of $12.35. The firm has a market cap of $187.30 million, a P/E ratio of -2.69 and a beta of -0.35.
Institutional investors and hedge funds have recently modified their holdings of the business. Acuta Capital Partners LLC purchased a new position in shares of Zafgen in the second quarter valued at approximately $2,558,000. Private Advisor Group LLC purchased a new position in shares of Zafgen in the second quarter valued at approximately $153,000. AlpInvest Partners B.V. purchased a new position in shares of Zafgen in the second quarter valued at approximately $1,436,000. Rhumbline Advisers purchased a new position in shares of Zafgen in the second quarter valued at approximately $214,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Zafgen in the second quarter valued at approximately $5,013,000. 81.55% of the stock is currently owned by institutional investors.
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Featured Story: Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.